Alkermes (company)

Alkermes plc
Company type	Public
Traded as	Nasdaq: ALKS; S&P 600 component;
Industry	Biotechnology
Founded	1987; 37 years ago
Founder	Michael Wall
Headquarters	Dublin, Ireland
Key people	Richard Pops (CEO)
Revenue	US$1.1 billion (2022)
Operating income	US$-20.5 million
Net income	US$-158 million (2022)
Total assets	US$1.9 billion
Total equity	US$1 billion
Number of employees	2,100
Website	www.alkermes.com

Alkermes plc is a fully-integrated

Élan Corporation, plc.^[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.^[1]

Products

Alkermes has four proprietary commercial drug products

opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone

for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include:

paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.^[6]^[7]

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, ALKS 2680. ALKS 2680 is in development for the treatment of narcolepsy.^[8]

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nevaleukin alfa.^[9]

References

^ ^a ^b Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
^ "Alkermes PLC".
^ "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
^ "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.
^ "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.
^ "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
^ "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
^ "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.
^ "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.

External links

Official website
Business data for Alkermes plc:

[abc-1] Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.

[2] "Alkermes PLC".

[3] "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.

[4] "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.

[5] "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.

[6] "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.

[7] "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.

[8] "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.

[9] "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.

[1]

[2]

[4]

[6]

[7]

[8]

[9]